Drug Trial Radar · NCT03643276
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
Last checked: Nov 19, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
5,000
Planned (sponsor's estimate)
Start
Jul 15, 2018
Primary completion
Jul 14, 2028
Study completion Jul 14, 2028
Sponsor
- Lead sponsor
- Martin SchrappeAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Deutsche Krebshilfe e.V., Bonn (Germany)
- First posted
- Aug 22, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Factorial
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The understanding of acute lymphoblastic leukemia (ALL) in childhood and adolescence has largely changed due to extensive genetic research in recent years: ALL is now considered to be a very heterogeneous disease group. The leukemia cells present themselves with quite differently activated regulatory mechanisms of the malignant phenotype. The introduction of more accurate methods of assessing therapy response ("minimal residual disease \[MRD\] tests") has provided new insights into very different mechanisms of action, including factors influenced by host factors; this has had practical clinical consequences for the use of more individualized therapy. Multimodal therapies have enabled a cure level of over 80% for ALL in this age group. However, the own and international study data show that the therapy toxicity of the contemporary chemotherapy concepts has become unacceptably high, in particular with respect to those intensified therapies used for the treatment of patients at high risk of ALL relapse. The AIEOP-BFM ALL 2017 study therefore aims for an innovative integrated approach that will not only adapt the risk stratification to new prognostic markers using more comprehensive diagnostics, but above all, qualitatively reorient the therapy. The most important consequence will be that this study is testing immunotherapy with the bispecific antibody blinatumomab as an alternative to particularly intensive and toxic chemotherapy elements in precursor B-cell ALL (pB-ALL) patients with detectable chemotherapy resistance and at high risk of relapse. With the aim to complement the effects of the conventional chemotherapy, Blinatumomab is in addition tested in the large group of pB-ALL patients at intermediate relapse risk with seemingly unremarkable leukemia, but who account for a large proportion of all relapses. Targeted therapy is also used in the form of the proteasome inhibitor bortezomib for patients with pB-ALL and slow response to the drugs of the induction chemotherapy with the aim to overcome intrinsic chemotherapy resistance of the ALL cells. In patients with T-lineage ALL, who have particularly poor chances for cure after relapse, the established consolidation chemotherapy has proved to be particularly effective. This chemotherapy phase is therefore tested in a longer and more intensive form in such T-ALL patients with intermediate or slow early treatment response with the aim to reduce the relapses rate in this subgroup.
Conditions
- Acute Lymphoblastic Leukemia, Pediatric
Interventions
BlinatumomabDrug
Experimental therapy in randomizations R-HR and R-MR
BortezomibDrug
Experimental therapy in randomization R-eHR
CyclophosphamideDrug
Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
CytarabineDrug
Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk
DaunorubicinDrug
Part of standard chemotherapy
MyocetDrug
Part of intensification block Myocet-FLA for patients with very high relapse risk
DexamethasoneDrug
Part of standard chemotherapy
DoxorubicinDrug
Part of standard chemotherapy
EtoposideDrug
Part of standard chemotherapy
Fludarabine PhosphateDrug
Part of intensification block Myocet-FLA for patients with very high relapse risk
IfosfamideDrug
Part of standard chemotherapy
6-MercaptopurineDrug
Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
MethotrexateDrug
Part of standard chemotherapy
PegaspargaseDrug
Part of standard chemotherapy
PrednisoloneDrug
Part of standard chemotherapy
TioguaninDrug
Part of standard chemotherapy
VincristineDrug
Part of standard chemotherapy
VindesineDrug
Part of standard chemotherapy
ErwinaseDrug
Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survivalTime frame: Assessed up to 120 months from start of study
- Disease-free survivalTime frame: Assessed up to 120 months from start of study
Locations
115 sites in 8 countries. Site status is shown where the registry gives one.
Sydney Children's Hospital
Sydney, Australia · Recruiting
The Children's Hospital at Westmead
Westmead, Australia · Recruiting
Univ.Klinik für Kinder- und Jugendheilkunde Graz
Graz, Austria · Recruiting
Univ.Klinik für Kinder- und Jugendheilkunde Innsbruck
Innsbruck, Austria · Recruiting
Kepler Universitätsklinikum
Linz, Austria · Recruiting
LKH Salzburg
Salzburg, Austria · Recruiting
St. Anna Kinderspital
Vienna, Austria · Recruiting
University Hospital Brno
Brno, Czechia · Recruiting
Regional Hospital České Budějovice
České Budějovice, Czechia · Recruiting
University Hospital Hradec Králové
Hradec Králové, Czechia · Recruiting
University Hospital Olomouc
Olomouc, Czechia · Recruiting
University Hospital Ostrava-Poruba
Ostrava-Poruba, Czechia · Recruiting
University Hospital Plzeň
Pilsen, Czechia · Recruiting
University Hospital Motol
Prague, Czechia · Recruiting
Masaryk´s Hospital Ústí nad Labem
Ústí nad Labem, Czechia · Recruiting
Kinderklinik der med. Fakultät der RWTH, Bereich Hämatologie/Onkologie
Aachen, Germany · Recruiting
I. Klinik für Kinder u. Jugendliche, Klinikum Augsburg, Hämatologie/ Onkologie
Augsburg, Germany · Recruiting
Klinikum Berlin-Buch II. Kinderklinik, Bereich Onkologie/Allg. Pädiatrie
Berlin, Germany · Recruiting
Kinderklinik der Charité, Campus Virchow Klinikum (CVK), Abt.: Kinderhämatologie
Berlin, Germany · Recruiting
Städtisches Krankenhaus, Kinderklinik
Braunschweig, Germany · Recruiting
Klinikum Chemnitz gGmbH, Klinik für Kinder- und Jugendmedizin, Hämatologie / Onkologie
Chemnitz, Germany · Recruiting
Kliniken der Stadt Köln GmbH, Kinderkrankenhaus Riehl
Cologne, Germany · Recruiting
Med. Einrichtungen der Universität zu Köln, Klinik für Allg. Kinderheilkunde, Onkologisch-hämatologische Station
Cologne, Germany · Recruiting
Carl-Thiem-Klinikum, Kinderklinik, Abt. Hämatologie/Onkologie
Cottbus, Germany · Recruiting
Vestische Kinder- u. Jugendklinik, Universitätsklinik Witten/Herdecke
Datteln, Germany · Recruiting
Klinikum Dortmund, Klinik f. Kinder- und Jugendmedizin
Dortmund, Germany · Recruiting
Universitatsklinikum Carl Gustav Carus
Dresden, Germany · Recruiting
Universitätsklinik
Düsseldorf, Germany · Recruiting
Helios Klinikum Erfurt GmbH, Klinik für Kinderheilkunde
Erfurt, Germany · Recruiting
Universitaets - Kinderklinik
Erlangen, Germany · Recruiting
Universitaetsklinikum Essen
Essen, Germany · Recruiting
Klinikum der J.W. Goethe Universitaet
Frankfurt, Germany · Recruiting
Universitaetskinderklinik - Universitaetsklinikum Freiburg
Freiburg im Breisgau, Germany · Recruiting
Klinikum der Justus-Liebig-Universität, Zentrum für Kinderheilkunde, Abt. Hämatologie/Onkologie
Giessen, Germany · Recruiting
Universitäts-Kinderklinik Päd. I, Hämatologie/Onkologie
Göttingen, Germany · Recruiting
Klinik und Poliklinik für Kinder und Jugendmedizin, Allgemeine Pädiatrie mit Poliklinik/Pädiatrische Onkologie und Hämatologie
Greifswald, Germany · Recruiting
Medizinische Hochschule Hannover, Zentrum Kinderheilkunde u. Jugendmedizin
Hanover, Germany · Recruiting
Universitäts-Kinderklinik, Päd. Onkologie, Hämatologie, und Immunologie
Heidelberg, Germany · Recruiting
Klinikum Heilbronn GmbH, Klinik für Kinderheilkunde und Jugendmedizin/Perinatalzentrum
Heilbronn, Germany · Recruiting
Gemeinschaftskrankenhaus Herdecke, Kinderabteilung
Herdecke, Germany · Recruiting
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.